Clover Health Investments (CLOV) Financials

Clover Health Investments (NASDAQ: CLOV) is showing a clear operational turnaround in 2025 and early 2026, with improving profitability, strong operating cash flow, and a relatively solid cash position. That said, the company is still operating with thin margins, heavy insurance claims expense, and a balance sheet that has become more leveraged than it was a year ago.

What stands out most in Q1 2026 is that Clover generated $749.2 million in revenue and $27.3 million in net income, compared with a $1.3 million loss in Q1 2025 and a larger loss in Q4 2025. Operating cash flow was also strong at $107.9 million, up from $5.4 million in Q2 2025 and $12.1 million in Q3 2025. That is a meaningful sign of improved business quality.

Revenue growth has been steady. Quarterly revenue rose from $462.3 million in Q1 2025 to $749.2 million in Q1 2026, driven by higher premiums earned. Premium revenue itself increased from $456.9 million in Q1 2025 to $744.2 million in Q1 2026. For a health insurance company, that is a strong top-line expansion trend.

However, Clover’s profitability remains fragile. The company’s biggest expense line is still property and liability insurance claims, which came in at $589.6 million in Q1 2026. While revenue covered expenses in the quarter, the margin buffer is not especially wide, so claims volatility remains a major risk for investors.

The balance sheet is mixed. As of March 31, 2026, Clover had $697.7 million in total assets, $358.3 million in liabilities, and $339.4 million in total equity. Cash and equivalents were $173.3 million, and trading securities added another $240.7 million. That gives the company liquidity, but liabilities have also risen materially from the prior year.

Compared with Q1 2025, liabilities are much higher at $358.3 million versus $247.6 million, while equity has increased only modestly. At the same time, retained earnings remain deeply negative at ($2.26 billion), reflecting Clover’s history of losses.

• Q1 2026 net income turned solidly positive at $27.3 million, versus a small loss a year earlier.
• Operating cash flow improved sharply to $107.9 million, suggesting better underlying cash generation.
• Revenue growth has been strong, with quarterly revenue up significantly year over year.
• Cash and investments remain substantial, supporting near-term liquidity.
• Premiums earned continue to rise, which is the main driver of the company’s growth.
• EPS was modest but positive at $0.05 in Q1 2026.
• Share count remains large, with more than 522 million weighted average basic shares in Q1 2026.
• Insurance claims remain the largest cost and could pressure margins if utilization trends worsen.
• Liabilities increased year over year, limiting the improvement in the balance sheet.
• Retained earnings are still deeply negative, showing the company has not yet built a long-term profit base.

Bottom line: Clover Health appears to be moving in the right direction operationally, with better revenue, improving cash flow, and a return to profitability in Q1 2026. Retail investors should view the stock as a turnaround story rather than a stable compounder. The key question going forward is whether Clover can keep claims costs under control and sustain positive earnings and operating cash flow over multiple quarters.